Ligufalimab
Modify Date: 2024-01-13 11:20:23
Ligufalimab structure
|
Common Name | Ligufalimab | ||
|---|---|---|---|---|
| CAS Number | 2428381-55-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LigufalimabLigufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1]. |
| Name | Ligufalimab |
|---|
| Description | Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Ligufalimab 结合人 CD47 抗原，EC50 值为 0.078 nM，KD 值为 0.152 nM[1]。 Ligufalimab (0-3000 nM) 不诱导红细胞血凝[1]。 Ligufalimab (0.1、1、10 µg/mL) 以剂量依赖性方式诱导 Raji、Jurkat 和 Ramos 细胞的吞噬作用[1]。 |
| In Vivo | Ligufalimab(0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) 抑制小鼠肿瘤生长[1]。 Animal Model: SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model)[1] Dosage: 0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model Administration: I.v. Result: Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg. |
| References |
| No Any Chemical & Physical Properties |